title: Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia.
abstract: Hemorrhages in the palpebral conjunctiva (HPCs) have been recorded in patients living in an area endemic for loiasis who developed serious reactions after ivermectin treatment. A study was designed to evaluate the frequency of these lesions, and to identify risk factors associated with their appearance. The conjunctivae of 1,682 patients who complained of reactions were systematically examined. HPCs were found in 41 patients. The initial mean Loa loa microfilaremia in the individuals with HPCs was 14,900 microfilariae (mf) per mL, as compared with 14.5 mf/mL in the other patients. Mansonella perstans microfilaremia and male gender were also associated with HPCs. Post-treatment fundus examinations were performed on 37 patients, and a close relationship was found between the occurrence of HPCs and the presence of retinal lesions. The vascular pathological processes leading to the ocular lesions may be similar to those which occur at the cerebral level in patients harboring high L. loa microfilaremia who develop neurologic troubles after ivermectin treatment. Retinal lesions may represent a special feature of the Loa-related encephalopathies useful for differential diagnosis, and the HPCs may be useful as an alarm sign to identify those individuals who might develop serious reactions after ivermectin treatment.
authors.affiliation: Department of Ophthalmology, Central Hospital, Yaounde, Cameroon.
authors.forename: G
authors.initials: G
authors.lastname: Fobi
authors.forename: J
authors.initials: J
authors.lastname: Gardon
authors.forename: M
authors.initials: M
authors.lastname: Santiago
authors.forename: D
authors.initials: D
authors.lastname: Ngangue
authors.forename: N
authors.initials: N
authors.lastname: Gardon-Wendel
authors.forename: M
authors.initials: M
authors.lastname: Boussinesq
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects* / Q000627:therapeutic use; D003229:Conjunctival Diseases / Q000139:chemically induced* / Q000473:pathology; D005130:Eye Hemorrhage / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000009:adverse effects* / Q000627:therapeutic use; D008117:Loa / Q000302:isolation & purification*; D008118:Loiasis / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018512:Parasitemia / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D012166:Retinal Hemorrhage / Q000139:chemically induced / Q000473:pathology; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; D007559:Ivermectin